News Story: Full Text
Sponsored By
Cleveland Clinic Brain Tumor and Neuro-Oncology Center
Please Click On The Above Banner For More Details
Braintumor Website

 

Carboplatin Effective Against Low-Grade Glioma


Posted on: 07/08/2002

Carboplatin Effective Against Low-Grade Glioma

Scientists from the Duke University Medical Center joined others to report on their assessment of tumor response rate and activity with use of carboplatin in stabilizing the growth of progressive low-grade glioma (J Clin Oncol 20[13]:2951-2958, 2002).

The team studied 81 children between 6 and 204 months of age who were given 560 mg/m² of carboplatin IV every 4 weeks or until their disease progressed, toxicity became unacceptable, or their maximum tumor response was achieved. The subjects received a median of 11 carboplatin cycles; the researchers followed subjects for a median of 55 months following enrollment.

The authors reported that the overall objective response was 28% and the overall disease stabilization rate was 85%. They also noted that the disease progressed in 11 patients on study and 14 after treatment ended. Mostly, myelosuppression was seen as a toxicity; this included grade 3/4 neutropenia in 56 patients and grade 3/4 thrombocytopenia in 40. The 3-year failure-free survival rate was 64%, and overall survival was 84%.

The team noted that patients diagnosed with diencephalic tumors had a worse failure-free survival and overall survival when compared with patients having tumors at other sites. However, significantly better overall survival was seen among patients diagnosed with neurofibromatosis type 1 with progressive low-grade glioma.

On the basis of these results, the researchers concluded that this schedule of carboplatin produced stabilization of disease or improvement in most children with progressive low-grade glioma. Toxicity reported was manageable. The team noted that better treatment strategies are needed for patients found to have diencephalic tumors in particular.

Source: http://www.cancernetwork.com/news/archive/020702e.htm
Click HERE to return to brain tumor news headlines


Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2019 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557
888-295-4740